Pharmaceuticals

Human Serum Albumin Market Growth Opportunities: Insights from 2025–2029

November 20, 2025 by Marketing Posting

Unlock Global Insights – Save 20% on Market Reports with Code ONLINE20

What Is The Anticipated Size Of The Human Serum Albumin Market Over The Five-Year Period 2025–2029?

The human serum albumin market has demonstrated substantial expansion over recent years. This market is projected to expand from $5.39 billion in 2024 to $5.79 billion by 2025, exhibiting a compound annual growth rate (CAGR) of 7.5%. Historically, this expansion has been driven by factors such as a rise in healthcare needs, the broadening uses of human serum albumin, a growing elderly population, heightened demand for blood plasma derivatives, and an increase in liver conditions and associated diseases.

The human serum albumin market is projected to experience substantial expansion in the coming years, reaching $7.63 billion by 2029, exhibiting a compound annual growth rate (CAGR) of 7.1%. This anticipated growth during the forecast period is due to factors such as increased availability of crucial medications, wider-ranging therapeutic uses, an increasing count of hospitals, developing healthcare infrastructure, and governmental efforts. Key developments expected in the forecast period encompass cell-free protein synthesis, CRISPR-based strain engineering, adoption of continuous manufacturing techniques, innovations in transdermal delivery systems, and progress in lyophilization.

Unlock Your Free Sample Report for Exclusive Market Data:

https://www.thebusinessresearchcompany.com/sample.aspx?id=27310&type=smp

What Are The Key Drivers Of Growth In The Human Serum Albumin Market?

The anticipated rise in liver disease cases is set to boost the human serum albumin market in the coming years. Liver diseases encompass various ailments that compromise liver function, such as hepatitis, fatty liver disease, cirrhosis, and liver cancer. The surge in liver diseases is primarily linked to the increasing rates of obesity, as excessive abdominal fat contributes to non-alcoholic fatty liver disease (NAFLD), leading to fat buildup, inflammation, and potential liver failure. Human serum albumin assists in managing liver disease by reestablishing blood volume, reducing fluid retention, protecting renal function, and improving prognoses for complications like ascites and hepatorenal syndrome. Illustratively, a July 2023 publication by the Office for Health Improvement & Disparities, a UK government department, revealed that hospital admissions where liver disease was the primary diagnosis saw a 22.0% increase in the financial year ending 2022, climbing from 67,458 cases in 2021 to 82,290 cases in 2022. Consequently, the increasing prevalence of liver diseases is a significant driver for the human serum albumin market.

What Are The Segment Types Shaping The Human Serum Albumin Market?

The human serum albumin market covered in this report is segmented

1) By Type Of Preparation: Recombinant Human Serum Albumin, Plasma-Derived Human Serum Albumin

2) By Formulation Type: Injection Solutions, Lyophilized Powder

3) By Distribution Channel: Direct Sales, Online Pharmacies, Third-party Distributors, Hospital Pharmacies

4) By Application: Volume Expanders, Drug Delivery Systems, Nutrition Enhancement, Diagnostic Agents

5) By End-User: Hospitals, Research Laboratories, Pharmaceutical Companies, Blood Banks

Subsegments:

1) By Recombinant Human Serum Albumin: Yeast-Based Recombinant Human Serum Albumin, Bacterial-Based Recombinant Human Serum Albumin, Plant-Based Recombinant Human Serum Albumin, Mammalian Cell-Based Recombinant Human Serum Albumin, Insect Cell-Based Recombinant Human Serum Albumin

2) By Plasma-Derived Human Serum Albumin: 5% Human Serum Albumin Solution, 20% Human Serum Albumin Solution, 25% Human Serum Albumin Solution, Lyophilized Human Serum Albumin, Fatty Acid-Free Human Serum Albumin

How Are Emerging Market Trends Shaping The Human Serum Albumin Industry Landscape?

Major companies operating in the human serum albumin market are increasingly focusing on creating advanced solutions, particularly animal-free recombinant excipients, to bolster product safety, expand scalability, and ensure compliance with regulatory frameworks in biomanufacturing processes. An animal-free recombinant excipient refers to an inactive biological substance engineered using recombinant DNA technology, devoid of any animal- or human-derived ingredients, thus guaranteeing high purity and safety in pharmaceutical and biomanufacturing contexts. For example, in April 2025, InVitri Inc., a US-based supplier of animal-free, recombinant proteins and excipients, launched Optibumin 25, which is the first recombinant 25% human serum albumin developed for closed-system biomanufacturing. This product is specifically optimized for downstream processing, formulation, and cryopreservation workflows, and is presently available in 100 mL single-use bags. Its animal-origin-free and chemically defined composition contributes to superior purity, consistency, and minimized contamination hazards. It is also GMP-ready, scalable for commercial production volumes, and offers a stable, sterile solution that seamlessly integrates into applications such as viral vector manufacturing, stem cell preservation, vaccine formulation, and regenerative medicine.

Who Are The Primary Competitors In The Global Human Serum Albumin Market?

Major companies operating in the human serum albumin market are Thermo Fisher Scientific Inc., Takeda Pharmaceutical Company Limited, Merck KGaA, CSL Behring (CSL), Baxter International Inc., Grifols S A, Sartorius AG, Octapharma AG, Kedrion Biopharma, Shanghai RAAS Blood Products Co Ltd., Biotest Aktiengesellschaft, LFB Group, Hualan Biological Engineering Inc., Taibang Biologic Group, Kamada Ltd., InVitria Inc., Reliance Life Sciences, Bio Products Laboratory, Mitsubishi Tanabe Pharma, and Sichuan Yuanda Shuyang Pharmaceutical Co Ltd.

Download The Full Report For Exclusive Market Findings:

https://www.thebusinessresearchcompany.com/report/human-serum-albumin-global-market-report

How Is Human Serum Albumin Market Demand Varying Across Different Regions?

North America was the largest region in the human serum albumin market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the human serum albumin market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

Request A Customized Version Of The Human Serum Albumin Market Report:

https://www.thebusinessresearchcompany.com/customise?id=27310&type=smp

Browse Through More Reports Similar to the Global Human Serum Albumin Market 2025, By The Business Research Company

Wall Decor Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/wall-decor-global-market-report

Painting And Wall Covering Contractors Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/painting-and-wall-covering-contractors-global-market-report

Commercial Flooring Global Market Report 2025

https://www.thebusinessresearchcompany.com/report/commercial-flooring-global-market-report

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 310-496-7795